Astrocyte

Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma

Retrieved on: 
Thursday, April 21, 2022
Regulation, Glioma, Investigational New Drug, Regulatory T cell, Brain, U.S. Securities and Exchange Commission, COVID-19, Security (finance), Research, Etal, Risk, Patient, LinkedIn, Securities Exchange Act of 1934, Forward-looking statement, FDA, Securities Act of 1933, Acute myeloid leukemia, SEER, GBM, IND, Adult, US Foods, Glioblastoma, Food, Incidence, Private Securities Litigation Reform Act, Company, Factor X, Partnership, Astrocyte, T-cell lymphoma, CEO, Growth hacking, Pharmacokinetics, Twitter, Drug Quality and Security Act, AML, STS, Radiation, SEC, Emory University, Safety, Virus, Survival, Mycobacterium wolinskyi, Neuron, Metastasis, Terminology, Form 10-K, Inflammation, T cell, Neoplasm, Person, DIPG, Antimetabolite, Cancer, Pharmaceutical industry, Vaccine, Medical imaging, Facebook

HOUSTON, April 21, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) is allowing the Company's Investigational New Drug (IND) application to study WP1066 for the treatment of recurrent malignant glioma. With this IND now cleared, Moleculin plans to evaluate strategic partnerships and collaborations to conduct a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1066 in adult patients with recurrent malignant glioma.

Key Points: 
  • With this IND now cleared, Moleculin plans to evaluate strategic partnerships and collaborations to conduct a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1066 in adult patients with recurrent malignant glioma.
  • "WP1066 has demonstrated significant anti-tumor activity in a wide range of tumor cell lines and increased survival in a number of animal models to-date.
  • WP1066 is currently being evaluated in collaboration with Emory University for the treatment of pediatric brain tumors, including Diffuse Interstitial Pontine Glioma (DIPG).
  • Forward-looking statements in this release include, without limitation, Moleculin's ability to secure a strategic partnership or collaboration to conduct a Phase 1 trial.

DGAP-News: Kadimastem Receives Grant for a Total Budget of NIS 10 Million ($3.1 million) from the Israeli Innovation Authority

Retrieved on: 
Saturday, March 5, 2022
Patient, HIV disease progression rates, R&D, VP, Stem cell, Israel Innovation Authority, Astrocyte, Israel Prize, Neurodegeneration, Risk, Innovation, Safety, Projection, FDA, Sclerosis, State Security Law in Bahrain, IIA, Molecular genetics, Company, Tel Aviv Stock Exchange, Weizmann Institute of Science, TASE, CSO, IND, History, Multiple sclerosis, Financial regulation, Emeritus, Technology, Glaucoma, KDST, ALS, Nervous system, Protocol, NASDAQ, Medical device, Pharmaceutical industry

Kadimastem CEO Asaf Shiloni said, "This grant is an important expression of trust by the Israeli Innovation Authority in Kadimastem and the potential of our clinical, cell therapy platform to provide millions of patients worldwide with life-saving treatments.

Key Points: 
  • Kadimastem CEO Asaf Shiloni said, "This grant is an important expression of trust by the Israeli Innovation Authority in Kadimastem and the potential of our clinical, cell therapy platform to provide millions of patients worldwide with life-saving treatments.
  • The Company is currently in one of the most significant periods in its history, both clinically and financially.
  • Prof. Michel Revel, Chief Scientist of Kadimastem: "We thank the Innovation Authority for supporting Kadimastem, its work and its vision."
  • This is the second grant awarded to Kadimastem in the past months by the IIA.

Horizon Therapeutics plc Partners with Christine Ha, First Blind Contestant and Winner of MasterChef, to Amplify Her Unstoppable NMOSD Story

Retrieved on: 
Wednesday, March 2, 2022
Other Consumer, Women, Other Health, Other Philanthropy, Men, Pharmaceutical, Optical, Consumer, Foundation, Philanthropy, Fitness & Nutrition, Entertainment, General Health, Biotechnology, Health, Other Education, General Entertainment, Celebrity, Education, Diagnosis, NMOSD, Patient, MasterChef, Science, Woman, Astrocyte, Cookbook, Pain scale, Neuromyelitis optica spectrum disorder, Central nervous system, Optic nerve, Twitter, Paralysis, Quality of life, B cell, NMO, Spinal cord, Inflammation, LinkedIn, Instagram, Cooking, Spectrum disorder, Multimedia, List of Facebook features, Disease, Medicine, Autoimmunity, Cell, Loss of Sensation, Education, Awareness, Brain, Nasdaq, Autoantibody, Optic neuritis, Cranial nerves, Courage, Pharmaceutical industry, Medical imaging, Dentistry, Vaccine, Wood drying, Facebook, Neuromyelitis Optica Spectrum Disorder (NMOSD), Horizon, NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD), HORIZON

Im excited to be part of this initiative and to hear how others living with NMOSD define themselves, outside of the condition.

Key Points: 
  • Im excited to be part of this initiative and to hear how others living with NMOSD define themselves, outside of the condition.
  • There can often be a long road to an accurate NMOSD diagnosis, and Christine has underscored the importance of education and self-advocacy to find answers.
  • We hope this initiative allows people living with NMOSD to learn from one another, and ultimately helps more people find answers.
  • For more information and additional resources, including a tips sheet from Ha for living with NMOSD, visit NMOSDWontStopMe.com .

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Monday, February 28, 2022
Biotechnology, Pharmaceutical, Health, Prescription, Annual report, Hallucination, RNA, Security (finance), ADP, Therapy, Osteoarthritis, RPD, Rett syndrome, Pain, Nasdaq, The Lancet, NDA, Form 10-K, Private Securities Litigation Reform Act, Research, Microglia, SYNGAP1, Growth, Stoke, Psychosis, Astrocyte, ACAD, Drug development, Disease, U.S. Securities and Exchange Commission, New Drug Application, Food, Pimavanserin, Delusion, Neurological disorder, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Twitter, Neuron, LinkedIn, Brain, Cognition, Patient, Central nervous system, Pain management, Schizophrenia, MECP2, Vanderbilt University, Dementia, Lists of diseases, Dopamine, Nature, Acquisition, Shanda, FDA, Histamine, Neurology, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., GAAP, Pharmaceutical industry, Lithium

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2021.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2021.
  • Net sales of NUPLAZID(pimavanserin) were $130.8 million for the fourth quarter of 2021, an increase of 8% as compared to $121.0 million reported for the fourth quarter of 2020.
  • Research and development expenses for the fourth quarter of 2021 were $67.1 million, compared to $62.1 million for the same period of 2020.
  • Acadia management will review its fourth quarter and full year financial results and operations via conference call and webcast today at 4:30 p.m. Eastern Time.

DGAP-News: Secarna Pharmaceuticals' partner Denali Therapeutics exercises option for LNAplusTM antisense oligonucleotide development program in neurodegeneration

Retrieved on: 
Wednesday, February 23, 2022
ASO, LNA, Therapy, Industry, Astrocyte, Mouse, Injection, Traffic barrier, Humanitarian use licenses, Neuron, Exercise, Biomarker, Asos, Gene expression, OTV, Global Research Collaboration for Infectious Disease Preparedness, Neurodegeneration, Brain, Drug discovery, Technology, CEO, Program, Transferrin receptor, CNS, BBB, Denali, Microglia, Fine chemical, Security (finance), Medical device, Pharmaceutical industry, Secarna's proprietary drug discovery and development platform, LNAplusTM, Secarna Pharmaceuticals GmbH & Co. KG, Denali Therapeutics Inc., SECARNA'S PROPRIETARY DRUG DISCOVERY AND DEVELOPMENT PLATFORM, LNAPLUSTM, SECARNA PHARMACEUTICALS GMBH & CO. KG, DENALI THERAPEUTICS INC.

Munich/Martinsried, Germany, February 22, 2022 - Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets, today announced that Denali Therapeutics Inc. ("Denali") has exercised its option to in-license an ASO program generated by Secarna through its proprietary drug discovery and development platform, LNAplusTM.

Key Points: 
  • Munich/Martinsried, Germany, February 22, 2022 - Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets, today announced that Denali Therapeutics Inc. ("Denali") has exercised its option to in-license an ASO program generated by Secarna through its proprietary drug discovery and development platform, LNAplusTM.
  • This program is part of the Research Collaboration and Option Agreement between the two companies and is the first project for which Denali has exercised an option.
  • Under the collaboration, Secarna is employing its LNAplusTM platform to generate ASO candidates against targets relevant for the treatment of neurodegenerative diseases.
  • "We are delighted that Denali has exercised the first option to take one of our ASO programs forward in development," said Alexander Gebauer, M.D., Ph.D., CEO of Secarna Pharmaceuticals.

Global Glioblastoma Multiforme Drug Forecast and Market Analysis to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 4, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Growth, Diagnosis, Traffic barrier, Temozolomide, Patient, III, IDH, OS, Astrocyte, Cancer, Tyrosine kinase inhibitor, Epidemiology, R, Human, BBB, Patent, Northwest Biotherapeutics, Astrocytoma, Research, GBM, CAGR, WHO, Disease, Method, MGMT, Investment, Industry, Therapy, Compound annual growth rate, Regorafenib, Review, Oil, Pharmaceutical industry, Fine chemical, Marketing, Medical device, Retail, Glioblastoma, Bevacizumab

Topline Glioblastoma Multiforme market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

Key Points: 
  • Topline Glioblastoma Multiforme market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Analysis of the current and future market competition in the global Glioblastoma Multiforme therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glioblastoma Multiforme market in the future.
  • Track drug sales in the global Glioblastoma Multiforme therapeutics market from 2020-2030.

Neuroregenerative Gene Therapy Treats Temporal Lobe Epilepsy in Rat Model

Retrieved on: 
Tuesday, January 4, 2022
Science, Progress in Neurobiology, Seizure, AAV, Hope, Associate, Hippocampus, Brain, Epilepsy, Interneuron, Stroke, Government budget balance, National Natural Science Foundation of China, Neuron, RATS, Lists of diseases, Astrocyte, Huntington's disease, GABAergic, NEUROD1, TLE, Research, Cell, Anticonvulsant, Temporal lobe epilepsy, Jinan University, Patient, Qi, Police Technology Department, Technology, Progress, Animal, Pharmaceutical industry, Vaccine, Neuroscience

In recent years, Chen's team has developed a novel neuroregenerative gene therapy that offers a potential new approach to treat a variety of neurological disorders.

Key Points: 
  • In recent years, Chen's team has developed a novel neuroregenerative gene therapy that offers a potential new approach to treat a variety of neurological disorders.
  • Neuroregenerative gene therapy is a new technology that uses viral vectors to deliver neural transcription factors to glial cells in the brain and directly convert glial cells into functional neurons in situ.
  • "This is the first time we apply neuroregenerative gene therapy to treat epilepsy and achieved success in animal models.
  • This new discovery has important guidance for future clinical applications using neuroregenerative gene therapy to treat different neurological disorders", Professor Chen pointed out the potential clinical significance of this study.

Emulate Brain-Chip to Study the Effects of Microgravity on Human Brain Physiology at the International Space Station

Retrieved on: 
Tuesday, December 21, 2021
Other Defense, White House, Federal Government, Other Health, Pharmaceutical, Medical Devices, Defense, Public Policy, Government, Genetics, Air, Transport, Clinical Trials, Biotechnology, Science, Other Science, Research, Health, Pericyte, Twitter, National Center for Advancing Translational Sciences, Founders Fund, ISS National Lab, Â, Environment, National Center for Research Resources, Health, National, LinkedIn, Astrocyte, Microglia, ISS, USB, Research, Disease, Scientist, Traffic barrier, Thumb, NASA, BBB, Harvard University, NCATS, Biology, Wyss Institute for Biologically Inspired Engineering, Immune system, Wyss Institute, NIH, Permeability, Perfusion, Engineering, Medical imaging, Emulate

The ISS provides an environment where researchers can study human health in microgravity, allowing them to isolate the effects of gravity from other factors that can impact brain cell function.

Key Points: 
  • The ISS provides an environment where researchers can study human health in microgravity, allowing them to isolate the effects of gravity from other factors that can impact brain cell function.
  • The Emulate Brain-Chip is the most comprehensive in vitro model of the human neurovascular unit, including the blood-brain barrier (BBB), for preclinical research.
  • It contains five cell types in a dynamic and tunable microenvironment, resulting in in vivo-like gene expression and phenotypic response.
  • The vascular channel is lined with brain microvascular endothelial cells, while the brain channel contains cortical neurons, astrocytes, pericytes, and microglia.

Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Study of CMV RNA-Pulsed Dendritic Cell Vaccine for the Treatment of Newly-Diagnosed Glioblastoma Patients

Retrieved on: 
Tuesday, November 30, 2021
Science, Other Science, Biotechnology, Research, Oncology, Health, Clinical Trials, Other Health, World Health Organization, ITI, Death, GBM, Company, Lysosome-associated membrane glycoprotein, Diagnosis, WHO, History, DNA, B cell, Biotechnology, Allergy, Infection, UNITE, Brain, Glioblastoma, World, Cancer, Acute myeloid leukemia, University, LAMP1, The Society of Neurological Surgeons, American Association of Neurological Surgeons, Duane Mitchell, Trial of the century, Degenerative disease, Partnership, American Brain Tumor Association, Human, Temozolomide, Vaccine, Survival, Adult, ATTAC, Therapy, American Association, Association, Patient, Duke University School of Medicine, LAMP, Duke University, Chemoradiotherapy, Antigen presentation, Astellas Pharma, Patent, Immunomics, RNA, Astrocyte, DC, CMV, Pharmaceutical industry, Glioblastoma (GBM), ITI-1000 and the Phase 2 (ATTAC-II) Study, UNITE, Immunomic Therapeutics, Inc., GLIOBLASTOMA (GBM), ITI-1000 AND THE PHASE 2 (ATTAC-II) STUDY, UNITE, IMMUNOMIC THERAPEUTICS, INC.

This is an extension of the Phase 2 ATTAC-II study ( NCT02465268 ) where eligibility is limited to those patients who have had surgery but have not yet received chemoradiation.

Key Points: 
  • This is an extension of the Phase 2 ATTAC-II study ( NCT02465268 ) where eligibility is limited to those patients who have had surgery but have not yet received chemoradiation.
  • ITIs dendritic cell vaccine is designed to target the pp65 viral antigen of Cytomegalovirus (CMV) that is expressed in GBM, but not in normal brain cells.
  • This dendritic cell vaccine is then returned to the patient.
  • The ATTAC-II study ( NCT02465268 ) is a Phase II randomized, placebo-controlled clinical trial enrolling patients with newly diagnosed GBM that will explore whether dendritic cell (DC) vaccines, including ITI-1000, targeting the CMV antigen pp65 improves survival.

Astrocyte Pharmaceuticals Announces Publication in the Journal Stroke of Results Supporting Advancement of AST-004 into the Clinic

Retrieved on: 
Monday, November 22, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Patient, Adenosine A1 receptor, University, Los Angeles, Brain, Hospital, Neurodegeneration, MD, University of Texas System, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Adenosine, Doctor of Philosophy, Anatomy, Manuscript, Infarction, Umbra, penumbra and antumbra, Concussion, Centers for Disease Control and Prevention, View, Administration, Astrocyte, Ischemia, Respiration (physiology), Reperfusion, University of Warwick, Traumatic brain injury, Cell Systems, CDC, Center, Department, Drug discovery, Primate, Pharmaceutical industry

The manuscript describes the results of pre-clinical studies using AST-004, Astrocytes lead drug candidate, for the treatment of stroke.

Key Points: 
  • The manuscript describes the results of pre-clinical studies using AST-004, Astrocytes lead drug candidate, for the treatment of stroke.
  • This key study in non-human primates was designed to reproduce what typically happens when human stroke patients are treated in the emergency room.
  • The results published today in Stroke show highly significant improvements across a number of metrics, with benefits beyond the current standard of care reperfusion by thrombectomy surgery.
  • The manuscript published in Stroke utilized a sophisticated non-human primate model of stroke with the study conducted by researchers from Astrocyte Pharmaceuticals and Hamamatsu Pharma Research, Inc. of Japan.